ArticleBMC public health2025
Socioeconomic disparities in urological cancers in iran: a systematic analysis for the Global Burden of Disease study 2019.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study examined the socioeconomic disparities across Iran's provinces regarding health measures for urological cancers, including bladder, kidney, prostate, and testicular cancers.
methodsWe analyzed the age-standardized incidence, prevalence, and death rates for 31 Iranian provinces using data from the Global Burden of Disease Study 2019 (2000-2019). Socioeconomic status was evaluated using principal components analysis, and health inequalities were measured with the concentration index (CI).
resultsFrom 2000 to 2019, there was an increase in the incidence and prevalence of all urological cancers and the mortality of prostate cancer. However, the mortality/incidence ratios for prostate and bladder cancers decreased. The highest CIs, 0.26 for prevalence and 0.24 for incidence were recorded for testicular cancer in 2000-2004, which decreased to 0.18 and 0.17 in 2015-2019. No remarkable inequality was found in kidney cancer measures or the death rates of bladder and prostate cancers. Persistent inequality was observed in testicular cancer death rates (CIs of 0.16 and 0.12 in 2000-2004 and 2015-2019). The mortality/incidence ratio for testicular cancer showed minor inequalities favoring the poorer provinces.
conclusionAge-standardized incidence and prevalence rates for bladder, prostate, and testicular cancers, as well as testicular cancer death rate, were higher in the better-off provinces. Poorer provinces had higher mortality/incidence ratios for testicular cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.